Clinical Trials · NCT05663515
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
- Phase
- N/A
- Recruitment status
- Recruiting
- Sponsor
- AstraZeneca
- Enrollment
- 24,000
- Start date
- Sep 2024
- Locations
- 8 sites, 7 countries
- Primary endpoint
- Incidence rate of primary diagnosis of pancreatic cancer among exenatide exposed population